High-Purity Erdafitinib Powder for Pharmaceutical Research & Development

Erdafitinib Powder is a specialized pharmaceutical research compound associated with selective fibroblast growth factor receptor (FGFR) inhibition and is widely studied in the context of FGFR-driven cancer biology. Also identified by CAS No. 1346242-81-6, erdafitinib has the molecular formula C₂₅H₃₀N₆O₂ and a reported molecular weight of 446.5 g/mol.

Our research-grade Erdafitinib Powder is intended for qualified laboratories, pharmaceutical research programs, analytical laboratories, and other professional settings requiring a clearly identified erdafitinib reference compound. Product specifications, analytical documentation, purity information, batch data, and storage requirements should always be verified against the applicable certificate of analysis and supplier documentation. Where to Buy Erdafitinib Powder online

Erdafitinib is scientifically notable because it functions as an inhibitor of fibroblast growth factor receptors. PubChem identifies it as a kinase inhibitor and describes its mechanism in relation to FGFR inhibition.

Important: Erdafitinib is a prescription medicine and should not be represented as an over-the-counter product, dietary supplement, or self-treatment product. The current U.S. prescribing information identifies BALVERSA (erdafitinib) as a kinase inhibitor indicated for appropriately selected adult patients with locally advanced or metastatic urothelial carcinoma carrying susceptible FGFR3 genetic alterations.

Premium Erdafitinib Powder for Research Applications

For pharmaceutical and biomedical research, accurate compound identification is essential. Erdafitinib Powder provides researchers with a defined small-molecule FGFR inhibitor for laboratory investigation, analytical method development, formulation research, and related scientific workflows.

Researchers evaluating erdafitinib should distinguish the active chemical compound from its marketed prescription formulation. The pharmaceutical product BALVERSA contains erdafitinib in tablet form, whereas a powder product may represent a chemical or research material supplied for laboratory purposes. The two should not be presented as interchangeable products. The official prescribing information describes BALVERSA as film-coated tablets for oral use.

For procurement teams and laboratory buyers, useful product information includes:

• Product name: Erdafitinib
• CAS number: 1346242-81-6
• Molecular formula: C₂₅H₃₀N₆O₂
• Molecular weight: 446.5 g/mol
• Compound class: Kinase inhibitor
• Research focus: FGFR signaling and targeted oncology research
• Physical form: Powder, subject to supplier specification
• Intended setting: Qualified laboratory and research use

PubChem identifies erdafitinib under several identifiers, including its CAS Registry Number, PubChem CID 67462786, and the synonym Balversa.

Buy Erdafitinib Powder for Laboratory and Pharmaceutical Research

Organizations sourcing Erdafitinib Powder should prioritize identity, purity, traceability, analytical documentation, and appropriate storage and handling information rather than relying solely on generic product descriptions.

A professional research-material specification should ideally provide appropriate documentation such as a certificate of analysis, batch or lot identification, analytical testing information, and applicable handling instructions. Buyers should verify that the material supplied corresponds to the required chemical identity before using it in any laboratory procedure.

Because erdafitinib is associated with an approved prescription medicine, marketing communications should clearly separate research material from approved therapeutic use. Current U.S. labeling states that patient selection for BALVERSA should be based on an FDA-approved companion diagnostic for the relevant FGFR3 alteration.

High-Quality Erdafitinib CAS 1346242-81-6 for Advanced Research

The chemical identity of a research compound is one of the most important considerations when establishing a reliable procurement workflow. Erdafitinib CAS 1346242-81-6 is catalogued by PubChem with the molecular formula C₂₅H₃₀N₆O₂ and molecular weight 446.5 g/mol.

Its chemical structure and physicochemical descriptors make it suitable for investigation in a variety of professional research contexts involving kinase signaling, medicinal chemistry, analytical chemistry, and drug-discovery programs.

Erdafitinib belongs to a broader class of targeted kinase inhibitors investigated for cancers driven by abnormal growth-factor signaling. Research into FGFR pathways is particularly relevant to understanding how alterations in receptor signaling can contribute to tumor development and progression.

For organizations purchasing the compound, CAS 1346242-81-6 is an important identifier that can help distinguish erdafitinib from similarly named compounds, metabolites, isotope-labelled materials, and other FGFR inhibitors.

Erdafitinib FGFR Inhibitor for Scientific Research

FGFR signaling is an important area of modern molecular oncology research. Erdafitinib is characterized as a fibroblast growth factor receptor inhibitor, with activity involving FGFR family signaling.

This makes erdafitinib relevant to research programs investigating:

• FGFR-mediated cellular signaling
• Kinase inhibitor pharmacology
• Targeted oncology
• Cancer biology
• Molecular diagnostics research
• Medicinal chemistry
• Drug-discovery screening
• Analytical method development
• Pharmaceutical formulation research
• Biomarker and genotype-directed therapeutic research

The clinical relevance of FGFR alterations is reflected in current regulatory information. The U.S. FDA states that erdafitinib was approved in January 2024 for certain adults with locally advanced or metastatic urothelial carcinoma containing susceptible FGFR3 genetic alterations after at least one prior line of systemic therapy.

Erdafitinib Powder Specifications and Quality Considerations

When sourcing a pharmaceutical research compound, buyers should evaluate more than the product name. A robust purchasing decision may include confirmation of chemical identity, purity, batch consistency, packaging, storage conditions, analytical documentation, and supplier quality procedures.

For Erdafitinib Powder, buyers may request relevant documentation such as:

1. Certificate of Analysis (CoA)
2. Batch or lot number
3. Chemical identity confirmation
4. Purity assay
5. Analytical chromatogram where applicable
6. Storage recommendations
7. Packaging information
8. Safety documentation where applicable
9. Product specification sheet
10. Traceability information

The molecular information reported by PubChem can be used as a reference when establishing compound identity: erdafitinib has the molecular formula C₂₅H₃₀N₆O₂ and molecular weight 446.5 g/mol.

Research-Grade Erdafitinib Powder for Professional Buyers

Professional buyers looking for research-grade erdafitinib should select suppliers capable of providing transparent technical information and appropriate documentation. Search visibility is important, but scientific accuracy and regulatory clarity are equally important for pharmaceutical and laboratory procurement.

A strong product page should therefore avoid unsupported claims such as “100% effective,” “cures cancer,” “guaranteed treatment,” or claims that a powder product is equivalent to an approved prescription formulation.

Instead, the product should be positioned accurately as a chemical/research material, with its identity, analytical specifications, intended use, and documentation clearly stated.

Erdafitinib Powder for Pharmaceutical Development and Drug Discovery

Erdafitinib has attracted scientific interest as a selective FGFR-targeting small molecule. Reviews of FGFR-targeted therapies identify erdafitinib among FDA-approved selective FGFR tyrosine kinase inhibitors.

Its relevance to pharmaceutical research extends beyond clinical oncology. Research teams may investigate the compound as part of broader programs involving receptor tyrosine kinase signaling, molecular pharmacology, drug screening, structure-activity relationships, and targeted therapeutic development.

For medicinal chemistry teams, accurate compound identification is especially important when comparing related kinase inhibitors. Erdafitinib’s unique chemical identity should therefore be communicated using its recognized name and CAS number rather than relying only on commercial brand terminology.

Order Erdafitinib Powder From a Qualified Research Supplier

When evaluating an Erdafitinib Powder supplier, buyers should consider:

• Verified chemical identity
• Consistent batch quality
• Transparent specifications
• Appropriate analytical documentation
• Professional packaging
• Reliable technical support
• Clear storage and handling information
• Regulatory compliance appropriate to the destination market
• Research-use classification where applicable

These considerations help procurement departments establish a more reliable sourcing process while reducing ambiguity between research chemicals and finished prescription medicines.

Erdafitinib Powder: Chemical Identification

Chemical name: Erdafitinib
CAS Number: 1346242-81-6
Molecular Formula: C₂₅H₃₀N₆O₂
Molecular Weight: 446.5 g/mol
PubChem CID: 67462786
Compound class: Kinase inhibitor / FGFR inhibitor

We provides the above core chemical identifiers and describes erdafitinib as a fibroblast growth factor receptor inhibitor.